Literature DB >> 32673124

Composite outcome measurement in clinical research: the triumph of illusion over reality?

Stephen P McKenna1,2, Alice Heaney1.   

Abstract

Composite measures that combine different types of indicators are widely used in medical research; to evaluate health systems, as outcomes in clinical trials and patient-reported outcome measurement. The potential advantages of such indices are clear. They are used to summarise complex data and to overcome the problem of evaluating new interventions when the most important outcome is rare or likely to occur far in the future. However, many scientists question the value of composite measures, primarily due to inadequate development methodology, lack of transparency or the likelihood of producing misleading results. It is argued that the real problems with composite measurement are related to their failure to take account of measurement theory and the absence of coherent theoretical models that justify the addition of the individual indicators that are combined into the composite index. All outcome measures must be unidimensional if they are to provide meaningful data. They should also have dimensional homogeneity. Ideally, a specification equation should be developed that can predict accurately how organisations or individuals will score on an index, based on their scores on the individual indicators that make up the measure. The article concludes that composite measures should not be used as they fail to apply measurement theory and, consequently, produce invalid and misleading scores.

Entities:  

Keywords:  C18; Composite measurement; Z00; clinical research; dimensional homogeneity; patient-reported outcome; unidimensionality

Mesh:

Year:  2020        PMID: 32673124     DOI: 10.1080/13696998.2020.1797755

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  11 in total

1.  Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma Therapies Invented by the Institute for Clinical and Economic Review.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2021-06-10

2.  Value Assessment, Real World Evidence and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2020-11-12

3.  Let a Thousand Models Bloom: ICER Analytics Opens the Floodgates to Cloud Pseudoscience.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2021-01-20

4.  To Dream the Impossible Dream: The Commitment by the Institute for Clinical and Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and Bladder Cancer Value Claims.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2020-12-10

5.  Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2021-02-16

6.  The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER).

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2020-07-31

7.  The Great I-QALY Disaster.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2020-07-31

8.  Nothing to Cheer About: Endorsing  Imaginary Economic Evaluations and Value Claims with CHEERS 22.

Authors:  Paul Langley
Journal:  F1000Res       Date:  2022-02-28

9.  Peter Rabbit is a Badger in Disguise: Deconstructing the Belief System of the Institute for Clinical and Economic Review in Health Technology Assessment.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2021-05-25

10.  Psychometric properties and diagnostic accuracy of the short form of the geriatric anxiety scale (GAS-10).

Authors:  Leonardo Carlucci; Matteo Balestrieri; Elisa Maso; Alessia Marini; Nadia Conte; Michela Balsamo
Journal:  BMC Geriatr       Date:  2021-06-30       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.